Overview

A class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Company’s common stock traded on the NASDAQ Stock Market under the symbol “VTRS.”

The Viatris class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Viatris securities between August 8, 2024, and February 26, 2025, both dates inclusive (the “Class Period”).

Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide.  The Company is headquartered in Pittsburgh, Pennsylvania with global centers in Shanghai, China and Hyderabad, India.

The Viatris class action lawsuit alleges that Defendants, throughout the Class Period, provided investors with material information concerning the failed inspection of Viatris’s Indore, India facility.  Defendants’ statements, albeit made months after the initial inspection and Defendants’ initiation of remediation efforts included, among other things, the disclosure of the U.S. Food and Drug Administration’s (“FDA”) issuance of a warning letter and import alert which would prevent Viatris from shipping 11 products from the Indore facility, though four of such were exempt from the limitations (the “Warning Letter”).  Defendants routinely referred to the impact of the Warning Letter as a mere “minor headwind” for the Company.

Defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris’s financials; notably, Defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts; Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to the Company’s existing financials and future projections, and for which the Company believed it would obtain exemptions.  Such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Viatris securities between August 8, 2024, to February 26, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Viatris class action lawsuit is June 3, 2025.